Finding hope by expanding the frontiers of therapy
We design ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases
Latest News
FTX-101 Phase 1 Clinical Trial Launched
First Subject Dosed with FTX-101. This study marks the beginning of a journey toward a…
Investissement Québec supports Find Therapeutics
Find Therapeutics today announced the closing of a $8.1 million (CAD$11 million) convertible note financing…
FDA clears Find’s IND for Phase 1 study of FTX-101
We are pleased to announce clearance of our IND by the U.S. Food and Drug…